Koers Vivoryon Therapeutics AG Euronext Amsterdam
Aandelen
DE0007921835
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 19,55 mln. 21,14 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -18 mln. -19,47 mln. | Nettowinst (verlies) 2025 * | 19 mln. 20,55 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | 19,55 mln. 21,14 mln. | Nettoliquiditeiten 2025 * | 6,7 mln. 7,25 mln. | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-1,05
x | K/w-verhouding 2025 * |
0,91
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 66,56% |
Recentste transcriptie over Vivoryon Therapeutics AG
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 01-01-12 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Director/Board Member | 56 | 31-08-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 74 | 01-01-07 | |
Director/Board Member | 54 | 01-01-07 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+29,03% | 48,16 mld. | |
-0,10% | 41,73 mld. | |
+43,45% | 41,03 mld. | |
-5,26% | 28,77 mld. | |
+11,48% | 25,59 mld. | |
-22,74% | 18,96 mld. | |
+9,06% | 12,92 mld. | |
+30,01% | 12,03 mld. | |
-1,51% | 11,77 mld. |